Trial Identifiers
Use the hyperlinks, where available to access additional clinical trial information.
Scientific Title
An Open-Label, Multicenter, Phase 1b/2 Study of the Safety and Efficacy of KRT-232 in Combination With Acalabrutinib in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma or Relapsed/Refractory Chronic Lymphocytic Leukemia
Commercial Sponsor
Kartos Therapeutics, Inc.
Summary
This is a non-randomised, open-label trial with two experimental cohorts. Experimental Cohort 1 is made up of participants with relapsed or refractory diffuse large B-cell lymphoma, and Experimental Cohort 2 is made up of relapsed or refractory chronic lymphocytic leukaemia. Both cohorts will receive KRT-232 and Acalabrutinib. KRT-232 will be administered orally, once daily, on days 1-7 in a 28-day cycle. Acalabrutinib will be administered 100mg, twice daily, continuously starting on Day 1 in a 28-day cycle.